Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics, Inc. (EWTX)
NASDAQ:EWTX
EWTX Stock Chart & Stats
$30.44
-$0.39(-1.54%)
At close: 4:00 PM EST
$30.44
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$10.60 - $31.82
Previous CloseN/A
Volume107.81K
Average Volume (3M)891.37K
Market Cap
$3.27B
Enterprise Value$3.17B
Total Cash (Recent Filing)$530.11M
Total Debt (Recent Filing)$3.99M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
May 07, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding107,270,520
10 Day Avg. Volume768,122
30 Day Avg. Volume891,372
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-17.64
Forecast
1Y Price Target
$40.29Price Target Upside32.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet And FinancingA strong balance sheet enables continued advancement of late-stage and early-stage programs and supports investment in commercial infrastructure, reducing the need for near-term dilutive financing ahead of key readouts.
Clinical Momentum For Cardiac ProgramInterim CIRRUS-HCM updates showing maintained ejection fraction and clinical activity at the tested dose levels reinforce confidence in EDG-7500's safety and efficacy profile ahead of full Part D data.
Regulatory And Market OpportunitySevasemten's positioning as a potential first approved therapy for Becker muscular dystrophy, combined with plans for regulatory submission and commercial preparation, could drive significant upside if pivotal trial outcomes are favorable.
Bears Say
Atrial Fibrillation Safety RiskAn additional new-onset atrial fibrillation case reported in Part D raises persistent safety concerns that could weigh on sentiment until longer-term safety data are available.
Phase 3 Readout RiskElevated rates of new-onset atrial fibrillation relative to expectations could temper enthusiasm and limit upside for the Phase 3 Becker muscular dystrophy readout expected in 4Q26.
Titration And Competitive DifferentiationThe presence of titration for EDG-7500, once viewed as a differentiator, now complicates the drug’s profile and may erode its competitive advantage if safety concerns persist.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics, Inc.’s price range in the past 12 months?
Edgewise Therapeutics, Inc. lowest stock price was $10.60 and its highest was $31.82 in the past 12 months.
What is Edgewise Therapeutics, Inc.’s market cap?
Edgewise Therapeutics, Inc.’s market cap is $3.27B.
When is Edgewise Therapeutics, Inc.’s upcoming earnings report date?
Edgewise Therapeutics, Inc.’s upcoming earnings report date is May 07, 2026 which is in 67 days.
How were Edgewise Therapeutics, Inc.’s earnings last quarter?
Edgewise Therapeutics, Inc. released its earnings results on Feb 26, 2026. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.436 by -$0.034.
Is Edgewise Therapeutics, Inc. overvalued?
According to Wall Street analysts Edgewise Therapeutics, Inc.’s price is currently Undervalued.
Does Edgewise Therapeutics, Inc. pay dividends?
Edgewise Therapeutics, Inc. does not currently pay dividends.
What is Edgewise Therapeutics, Inc.’s EPS estimate?
Edgewise Therapeutics, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Edgewise Therapeutics, Inc. have?
Edgewise Therapeutics, Inc. has 107,270,520 shares outstanding.
What happened to Edgewise Therapeutics, Inc.’s price movement after its last earnings report?
Edgewise Therapeutics, Inc. reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.436. Following the earnings report the stock price went down -1.527%.
Which hedge fund is a major shareholder of Edgewise Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.29 (32.36% Upside)
$40.29 (32.36% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.34%
12-Months-Change
Fundamentals
Return on Equity
-34.19%
Trailing 12-Months
Asset Growth
13.51%
Trailing 12-Months
Company Description
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$40.29
▲(32.36% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
1.40% Insiders
11.53% Mutual Funds
8.09% Other Institutional Investors
70.27% Public Companies and
Individual Investors